Page 17 - Presentation Time News Today

The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been...

Addition of Affimed’s innate cell engager improves cytotoxicity of natural killer cells and CAR-NK cellsNK cells with ICE® show at least comparable anti-tumor cell efficacy to CAR-NK cells with...

/PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company developing SRP-001, a first-in-class...

SEATTLE, Sept. 22, 2023 -- Rover Group, Inc. , the world’s largest online marketplace for pet care, today announced that management will present at the following investor conference: Jefferies...

SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rover Group, Inc. (NASDAQ:ROVR) ("Rover" or the "Company"), the world's largest online marketplace for pet care, today announced that management will present at the following

A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic activity of AB-101 against tumor cells and... | June 9, 2023

A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic...

SAR'579/IPH6101, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by

LEXINGTON, Mass., May 04, 2023 -- Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients... | May 4, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...